AQST - ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
2024-06-25 14:10:10 ET
Summary
- ARS Pharmaceuticals stock has recovered since the FDA's Complete Response Letter regarding its epinephrine nasal spray, neffy.
- Despite competition and a delayed market entry, ARS Pharmaceuticals remains ahead with its unique nasal spray, aiming for a significant market share.
- With substantial cash reserves, ARS is financially stable until 2029, though increased expenses are anticipated as the product launch nears.
- SPRY stock is a hold, suited for a barbell strategy portfolio, balancing high risk/reward potential amidst significant competitive and regulatory risks.
Investment Outlook on ARS Pharmaceuticals After FDA Setback Recovery
ARS Pharmaceuticals, Inc. ( SPRY ) stock has recovered admirably since my last update, which followed the U.S. FDA's Complete Response Letter [CRL] issued in September regarding their epinephrine nasal spray, neffy....
ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles